Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 6/20 | 0.66 |
| ▸ | P2RX4 | Q99571 | 5/20 | 0.66 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.66 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.66 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.63 |
| ▸ | SRC | P12931 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | RNASEL | Q05823 | 3/20 | 0.61 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.59 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.59 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.59 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26027907 | 1.00 | P2RX3 (0.66) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL22837327 | 0.99 | P2RX1 (0.64) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL23790862 | 0.92 | P2RY1 (0.65) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL21465098 | 0.91 | P2RX3 (0.68) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL16081086 | 0.91 | P2RX3 (0.68) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL30023799 | 0.91 | P2RX3 (0.68) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL21465101 | 0.91 | P2RX3 (0.68) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL14853798 | 0.90 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL23748621 | 0.90 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2P2RY1 | |
| SCHEMBL21008117 | 0.90 | P2RX3 (0.67) | P2RX3P2RX4P2RX1P2RX2P2RY1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2024-07-18 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4234565-A2 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11707480-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20210275563-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2021-09-09 | — | — | US | disclosed |
| US-10874687-B1 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2020-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707480-B2 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | P2RX3 122/4885P2RX4 125/4885P2RX1 68/4885 |
| US-10874687-B1 | Highly active compounds against COVID-19 | PNP, MTAP, ACE2 | P2RX3 122/4885P2RX4 125/4885P2RX1 68/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | P2RX3 138/4885P2RX4 124/4885P2RX1 90/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | P2RX3 138/4885P2RX4 124/4885P2RX1 90/4885 |
| US-20210275563-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, MTAP, ACE2 | P2RX3 122/4885P2RX4 125/4885P2RX1 68/4885 |
| US-20240238324-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | PNP, MTAP, ACE2 | P2RX3 122/4885P2RX4 125/4885P2RX1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.